Possibility of heart failure pharmacological treatment modification on the example of mineralocorticoid receptor antagonists – experience of Ostróda center Case report
Article Sidebar
Main Article Content
Abstract
According to the current guidelines of the European Society of Cardiology concerning the diagnosis and treatment of acute and chronic heart failure mineralocorticoid receptor antagonists – spironolactone or eplerenone – are recommended in all symptomatic patients (despite treatment with angiotensin converting enzyme inhibitors and β-blocker) and LVEF ≤ 35% to reduce mortality and hospitalizations. The paper presents a clinical case which illustrates the ability to modify treatment of chronic heart failure in a patient with a history of myocardial infarction and side effects of pharmacotherapy with spironolactone.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Kuch M., Syska-Sumińska J., Janiszewski M.: Hamowanie działania aldosteronu w niewydolności serca – nowa szansa na poprawę rokowania? Kardioprofil (wydanie specjalne) 2007; 5: 6-13.
3. Rocha R., Funder J.W.: The pathophysiology of aldosterone in the cardiovascular system. Ann. N. Y. Acad. Sci. 2002; 970: 89-100.
4. Gómez Sánchez E.P.: What is the role of the central nervous system in mineralocorticoid hypertension? Am. J. Hypertens. 1991; 4: 374-381.
5. Lombes M., Alfaidy N., Eugene E. et al.: Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation 1995; 92: 175-182.
6. Takeda Y., Miyamori I., Yoneda T. et al.: Production of aldosterone in isolated rat blood vessels. Hypertension 1995; 25: 170-173.
7. Struthers A.D.: Aldosterone blockade in cardiovascular disease. Heart 2004; 90: 1229-1234.